Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Withdrawn × marizomib × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 49 Radiotherapy 46 Cisplatin 38 Paclitaxel 37 Gemcitabine 35 Cyclophosphamide 34 Carboplatin 33 Dexamethasone 31 Nivolumab 30 Fluorouracil 29 Docetaxel 28 Bevacizumab 28 Oxaliplatin 26 Leucovorin 23 durvalumab 22 Rituximab 22 Magnetic Resonance Spectroscopy 22 Capecitabine 20 Pemetrexed 18 Drug Therapy 18 atezolizumab 17 Radiosurgery 17 Cytarabine 17 Radiation 16 Doxorubicin 16 Bortezomib 16 Prednisone 15 Etoposide 14 fludarabine 13 Lenalidomide 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05050305 2024-07-16

Marizomib Central Nervous System (CNS)

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡